A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
11/15/2023
Locations: Western Washington Medical Group (WWMG) - Everett - Silver Lake Medical Center Location, Everett, Washington
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
11/03/2023
Locations: Western Washington Medical Group (WWMG) - Everett - Silver Lake Medical Center Location, Everett, Washington +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
NCT05671835
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
10/19/2023
Locations: MedStar Georgetown University Hospital, Georgetown, Washington
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
IPF mHealth Exercise
NCT04838275
Recruiting
Patients with idiopathic pulmonary fibrosis (IPF) who are stable on antifibrotic therapy at least 3 months will be randomized to complete a 12-week home exercise intervention using an mHealth platform, plus a pre- and post-intervention monitoring period (4 weeks each) and in-person study assessments.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/10/2023
Locations: University of Washington, Seattle, Washington
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
NCT04300920
Recruiting
The purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard care with matched placebo plus standard of care in patients diagnosed with idiopathic pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function [10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or all-cause mortality] The secondary objectives w... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
03/21/2023
Locations: University of Washington, Seattle, Washington
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Quality of Life in IPF - Patient and Physician Perceptions
NCT04148157
Recruiting
This study aims to evaluate the differences between patient's and their physicians' perception of quality of life and the effect of disease severity and co-morbidities. Patients and physicians will complete two sets of questionnaires at an initial clinic visit and again six months later.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/12/2019
Locations: University of Washington - Center for Interstitial Lung Disease, Seattle, Washington
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates